Completed PHASE1 INTERVENTIONAL NCT00658970

Evaluation of KX2-391 in Patients With Advanced Malignancies

A Combined Rising Single-dose (RSD) and Rising Multiple-dose (RMD)Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies

Sponsor: Athenex, Inc.

Conditions Lymphoma Solid Tumors

Interventions KX2-391

Updated 7 times since 2017 Last updated: Jun 7, 2011 Started: Nov 30, 2007 Primary completion: Mar 31, 2010 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00658970, this PHASE1 trial focuses on Lymphoma and Solid Tumors and remains completed. Sponsored by Athenex, Inc., it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
May 2018 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — May 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Athenex, Inc.

Data source: Athenex, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States
• Philadelphia, United States